Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Invir.IO

    Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors

    20200515 BT-001_AACR curtain raiser EN

    Published 15 May 2020
    Categorized as 2020, BT-001, Invir.IO, Press release

    BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

    Poster BT-001Marchand, Semmrich, Fend et al.Immuno-Oncology summitDownload the poster herePoster Presentation

    Published 11 March 2020
    Categorized as 2020, BT-001, BT-001 (EN), Invir.IO, Publication

    Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

    20191211 PR preclinical BT001 EN

    Published 11 December 2019
    Categorized as 2019, BT-001, Invir.IO, Press release

    Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming

    Transgene SITC 2019 Poster Jean-Baptiste Marchand et al. SITC 2019 Download the poster here Poster Presentation

    Published 6 November 2019
    Categorized as 2020, Invir.IO, Publication

    Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies

    20190502 – TG-AZ agreement – ENG

    Published 2 May 2019
    Categorized as 2019, Invir.IO, Press release

    Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

    20190326 PR BioInvent extension CDR US

    Published 26 March 2019
    Categorized as 2019, Invir.IO, Press release

    Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment

    Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden

    Published 7 November 2018
    Categorized as 2018, Invir.IO, Publication

    Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference

    20181107 SITC Poster EN

    Published 7 November 2018
    Categorized as 2018, Invir.IO, Myvac, Press release

    Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody

    20181107 SITC Joint BioInvent Transgene EN

    Published 7 November 2018
    Categorized as 2018, Invir.IO, Press release

    Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference

    20181001 SITC Poster VEN

    Published 2 October 2018
    Categorized as 2018, Invir.IO, Myvac, Press release

    Posts navigation

    Newer posts Page 1 … Page 4 Page 5 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo